Citations

Showing 10 of 108104 citations.

Pineal cyst: results of long-term MRI surveillance and analysis of growth and shrinkage rates
Helal, Ahmed , Kashiwabara, Kosuke , Meyer, Fredric B. , Inoue, Akitoshi , Hasegawa, Hirotaka

Mayo Clinic

Journal of Neurosurgery | May 28, 2022 | Volume: 138 | Issue: 1 | Pages: 113-119

10.3171/2022.4.jns22276 | PMID 35623363 Get It

OBJECTIVE Pineal cyst (PC) is a relatively common true cyst in the pineal gland. Its long-term natural course remains ill defined. This study aims to evaluate the long-term natural history of PC and examine MRI risk factors for cyst growth and shrinkage to help better define which patients might benefit from surgical intervention. METHODS The records and MRI of 409 consecutive patients with PC were retrospectively examined (nonsurgical cohort). Cyst growth and shrinkage were defined as a ≥ 2-mm increase and decrease in cyst diameter in any direction, respectively. In addition to size, MRI signal intensity ratios were analyzed. RESULTS The median radiological follow-up period was 10.7 years (interquartile range [IQR] 6.4–14.3 years). The median change in maximal diameter was −0.6 mm (IQR −1.5 to 1.3 mm). During the observation period, cyst growth was confirmed in 21 patients (5.1%). Multivariate logistic regression analysis revealed that only age (odds ratio [OR] 0.96, 95% confidence interval [CI] 0.93–0.99, p < 0.01) was significantly associated with cyst growth. No patient required resection during the observation period. Cyst shrinkage was confirmed in 57 patients (13.9%). Multivariate analysis revealed that maximal diameter (OR 1.22, 95% CI 1.12–1.35, p < 0.01) and cyst CSF T2 signal intensity ratio (OR 9.06, 95% CI 1.38–6.62 × 101, p = 0.02) were significantly associated with cyst shrinkage. CONCLUSIONS Only 5% of PCs, mainly in patients younger than 50 years of age, have the potential to grow, while cyst shrinkage is more likely to occur across all age groups. Younger age is associated with cyst growth, while larger diameter and higher signal intensity on T2-weighted imaging are associated with shrinkage. Surgery is rarely needed for PCs, despite the possibility of a certain degree of growth.
IPP Improvements-Recent Innovations, Current Iterations, and Developments in the Pipeline
Habashy, Engy, Bole, Raevti , Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | May 28, 2022 | Volume: 19 | Issue: 11 | Pages: 1604-1607

10.1016/j.jsxm.2022.04.011 | PMID 35637098 Get It

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
Muñoz, Javier , Wang, Michael , Munoz, Javier L , Wang, Yucai , Jain, Preetesh

Mayo Clinic

Therapeutic Advances in Hematology | May 28, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/20406207221093980 | PMID 35651781 Get It

The availability of Bruton tyrosine kinase (BTK) inhibitors has brought about a paradigm shift in the treatment of patients with B-cell lymphomas and chronic lymphocytic leukemia. BTK was clinically validated as a target by the efficacy of the first-in-class inhibitor ibrutinib. The extended survival conferred by BTK inhibitors has brought long-term tolerability to the foreground. To minimize toxicities thought to be attributable to off-target kinase inhibition, a next generation of BTK inhibitors with greater selectivity was developed. In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenström macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20–based therapy. Because few head-to-head comparative trials of BTK inhibitors have so far been reported, no BTK ‘inhibitor of choice’ can be identified. Zanubrutinib has promising efficacy in its approved indications and appears to have reduced cardiac toxicities, particularly atrial fibrillation, which may influence the choice of BTK inhibitor treatment by prescribers. Further studies are needed to inform on optimal treatment sequencing of zanubrutinib and its combination with other agents. Here, we summarize existing clinical evidence for its efficacy and safety in mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and other B-lymphoproliferative indications. Plain Language Summary Zanubrutinib is a drug that was shown to effectively treat cancer of B cells without causing excessive serious side effects Patients with certain B-cell malignancies (cancers of white blood cells) benefit from treatment with Bruton tyrosine kinase (BTK) inhibitors, drugs that block the BTK protein and keep cancer from growing and spreading. Patients experience extended survival with ibrutinib, the first-generation BTK inhibitor approved by US Food and Drug Administration (FDA); however, one in five patients quit treatment because of harmful side effects. Ibrutinib-related side effects such as increased risk of bleeding, atrial fibrillation (abnormal heart rhythm), and high blood pressure are thought to be caused by ibrutinib blocking other proteins besides the intended target protein BTK. To reduce these side effects, zanubrutinib, a next-generation BTK inhibitor, was designed to block BTK more specifically than ibrutinib. Results of clinical studies on zanubrutinib treatment appear promising in patients with several types of B-cell malignancies, including mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia, and small lymphocytic lymphoma. There are not yet enough clinical data to determine which BTK inhibitor is most effective in treating B-cell malignancies without causing harmful side effects. Early data from the phase 3 ALPINE clinical study suggest that zanubrutinib works better than ibrutinib, and fewer patients experience side effects and quit treatment. Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20–based therapy.
Postmastectomy Breast Reconstruction is Safe in Patients on Chronic Anticoagulation
Yan, María , Manrique, Oscar J. , Tran, Nho V. , Harless, Christin A., Martinez‐Jorge, Jorys, Nguyen, Minh-Doan T. , Martinez-Jorge, Jorys, Kuruoglu, Doga , Boughey, Judy C.

Mayo Clinic

Archives of Plastic Surgery | May 27, 2022 | Volume: 49 | Issue: 03 | Pages: 346-351

10.1055/s-0042-1744405 | PMID 35832147 Get It

Abstract Background Postmastectomy breast reconstruction (PMR) increases patient satisfaction, quality of life, and psychosocial well-being. There is scarce data regarding the safety of PMR in chronic anticoagulated patients. Perioperative complications can reduce patient satisfaction; therefore, it is important to elucidate the safety of PMR in these patients. Methods A retrospective case–control study of patients who underwent PMR with implants and were on chronic anticoagulation was performed at our institution. Inclusion criteria were women ≥ 18 years old. Exclusion criteria included autologous reconstructions, lumpectomy, and oncoplastic procedures. Two controls for every one patient on anticoagulation were matched by age, body mass index, radiotherapy, smoking history, type of reconstruction, time of reconstruction, and laterality. Results From 2009 to 2020, 37 breasts (20 patients) underwent PMR with implant-based reconstruction and were on chronic anticoagulation. A total of 74 breasts (40 patients) who had similar demographic characteristics to the cases were defined as the control group. Mean age for the case group was 53.6 years (standard deviation [SD] = 16.1), mean body mass index was 28.6 kg/m2 (SD = 5.1), and 2.7% of breasts had radiotherapy before reconstruction and 5.4% after reconstruction. Nine patients were on long-term warfarin, six on apixaban, three on rivaroxaban, one on low-molecular-weight heparin, and one on dabigatran. The indications for anticoagulation were prior thromboembolic events in 50%. Anticoagulated patients had a higher risk of capsular contracture (10.8% vs. 0%, p = 0.005). There were no differences regarding incidence of hematoma (2.7% vs. 1.4%, p = 0.63), thromboembolism (5% vs. 0%, p = 0.16), reconstructive-related complications, or length of hospitalization (1.6 days [SD = 24.2] vs. 1.4 days [SD = 24.2], p = 0.85). Conclusion Postmastectomy implant-based breast reconstruction can be safely performed in patients on chronic anticoagulation with appropriate perioperative management of anticoagulation. This information can be useful for preoperative counseling on these patients.
An Automated Technique for the Measurement of Limb Occlusion Pressure During Blood Flow Restriction Therapy Is Equivalent to Previous Gold Standard
Abbas, Muhammad J. , Dancy, Malik E. , Marigi, Erick M. , Khalil, Lafi S. , Jildeh, Toufic R. , Buckley, Patrick J. , Gillett, Javair , Burgos, William D. , Okoroha, Kelechi R. , Marigi, Erick , Buckley, Patrick J., Gillett, Javair, Burgos, William

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | May 27, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1016/j.asmr.2022.04.002 | PMID 35747637 Get It

Purpose To evaluate the efficacy of an automated pneumatic torniquet pump and its ability to automatically calculate the limb occlusion pressure (LOP), as compared with the manual Doppler ultrasound technique. Methods Participants presenting to a Sports Medicine clinic were evaluated for study enrollment. Participants were fitted with a pneumatic tourniquet for the upper and lower extremity. LOP measurements were taken with a Doppler ultrasound or automated SmartCuffs PRO device in a randomized order. Results Final analysis was performed on 96 limbs (48 upper extremities and 48 lower extremities). The study population had a mean age 37.1 ± 14.7 years old and a mean body mass index of 25.47 ± 3.80. The mean measured LOP pressure on the upper extremity with Doppler ultrasound was 174.0 ± 48.7 mm Hg with a range from 120 to 282 mm Hg, whereas the mean measured LOP by the automated pump was 184.0 ± 44.9 mm Hg with a range from 135 to 266 mm Hg. There was no statistically significant difference found between the Doppler LOP and the Smart Cuff upper extremity LOP ( P = .29). When evaluating LOP pressure on the lower extremity the mean LOP found with the Doppler ultrasound was 195.0 ± 31.9 mm Hg with a range from 160 to 272 mm Hg, whereas the automated pump the mean LOP was 205.0 ± 27.1 mm Hg with a range from 168 to 278 mm Hg. There was no statistically significant difference found between the Doppler LOP and the automated pump lower extremity LOP ( P = .09). Conclusions No difference in the personalized LOP measurement was found when comparing an automated pump with the current gold standard of manual Doppler ultrasound. No patients companied of pain or discomfort during the LOP measurement. Level of Evidence Level II, diagnostic: prospective cohort study.
Gastrointestinal Manifestations in Hospitalized Children With Acute SARS-CoV-2 Infection and Multisystem Inflammatory Condition: An Analysis of the VIRUS COVID-19 Registry
Sayed, Imran A., Bhalala, Utpal , Strom, Larisa, Michaud, Kristina , Gharpure, Varsha , Heneghan, Julia A. , Irby, Katherine , Gupta, Neha , Gupta, Manoj , Boman, Karen , Bansal, Vikas , Kumar, Vishakha K. , Investigators, on behalf of the VIRUS, Markić, Joško , Asghar, Muhammad Sohaib , Blatz, Allison M. , Bansal, Vikas , Gharpure, Varsha P , Asghar, Muhammad S , Tripathi, Sandeep , Kim, John S. , Chiotos, Kathleen , Dapul, Heda , Bjornstad, Erica C. , Montgomery, Vicki , Kashyap, Rahul , Walkey, Allan J. , Gist, Katja M. , Investigators, on behalf of the VIRUS

Mayo Clinic

Pediatric Infectious Disease Journal | May 27, 2022 | Volume: 41 | Issue: 9 | Pages: 751-758

10.1097/inf.0000000000003589 | PMID 35622434 Get It

Background: Describe the incidence and associated outcomes of gastrointestinal (GI) manifestations of acute coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in hospitalized children (MIS-C). Methods: Retrospective review of the Viral Infection and Respiratory Illness Universal Study registry, a prospective observational, multicenter international cohort study of hospitalized children with acute COVID-19 or MIS-C from March 2020 to November 2020. The primary outcome measure was critical COVID-19 illness. Multivariable models were performed to assess for associations of GI involvement with the primary composite outcome in the entire cohort and a subpopulation of patients with MIS-C. Secondary outcomes included prolonged hospital length of stay defined as being >75th percentile and mortality. Results: Of the 789 patients, GI involvement was present in 500 (63.3%). Critical illness occurred in 392 (49.6%), and 18 (2.3%) died. Those with GI involvement were older (median age of 8 yr), and 18.2% had an underlying GI comorbidity. GI symptoms and liver derangements were more common among patients with MIS-C. In the adjusted multivariable models, acute COVID-19 was no associated with the primary or secondary outcomes. Similarly, despite the preponderance of GI involvement in patients with MIS-C, it was also not associated with the primary or secondary outcomes. Conclusions: GI involvement is common in hospitalized children with acute COVID-19 and MIS-C. GI involvement is not associated with critical illness, hospital length of stay or mortality in acute COVID-19 or MIS-C.
Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease
Kerur, Basavaraj , Fiedler, Karoline , Stahl, Marisa G. , Hyams, Jeffrey S. , Stephens, Michael C., Lu, Ying , Pfefferkorn, Marian, Alkhouri, Raza, Strople, Jennifer , Kelsen, Judith R. , Siebold, Leah, Goyal, Alka , Rosh, Joel R. , LeLeiko, Neal S. , Limbergen, Johan Van , Maltz, Ross , Karam, Lina , Heyman, Melvin B. , Benkov, Keith , Noe, Joshua D. , Moulton, Dedrick E., Pappa, Helen, Galanko, Joseph A. , Muise, Aleixo M. , Stephens, Michael, Leleiko, Neal S , Guerrerio, Anthony L. , Crowley, Eileen , Griffiths, Anne Marie , Deneau, Mark , Snapper, Scott B. , Kappelman, Michael D. , Benchimol, Eric I.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | May 27, 2022 | Volume: 75 | Issue: 1 | Pages: 64-69

10.1097/mpg.0000000000003464 | PMID 35622080 Get It

Background:Research on the utilization and effectiveness of antitumor necrosis factor (TNF) biologics in children with very early onset inflammatory bowel disease (VEOIBD) is urgently needed. Here we describe anti‐TNF use and durability in a multicenter cohort.Methods:We performed a retrospective cohort study of patients diagnosed with VEOIBD (<6 years) between 2008 and 2013 at 25 North American centers. We performed chart abstraction at diagnosis and 1, 3, and 5 years after diagnosis. We examined the rate of initiation and durability of infliximab and adalimumab and evaluated associations between treatment durability and the following covariates with multivariate Cox proportional hazard regression: age at diagnosis, sex, disease duration, disease classification, and presence of combined immunomodulatory treatment versus monotherapy.Results:Of 294 children with VEOIBD, 120 initiated treatment with anti‐TNF therapy and 101 had follow‐up data recorded [50% Crohn disease (CD), 31% ulcerative colitis (UC), and 19% IBD unclassified (IBD‐U)]. The cumulative probability of anti‐TNF treatment was 15% at 1 year, 30% at 3 years, and 45% at 5 years from diagnosis; 56 (55%) were treated between 0 and 6 years old. Anti‐TNF durability was 90% at 1 year, 75% at 3 years, and 55% at 5 years. The most common reason for discontinuation of anti‐TNF were loss of response in 24 (57%) children. Children with UC/IBD‐U had lower durability than those with CD (hazard ratio [HR] 0.17; 95% confidence interval [CI], 0.06–0.51; P = 0.001).Conclusions:Utilization and durability of anti‐TNF in VEOIBD is relatively high and comparable with older children. Having Crohn disease (compared with UC/IBD‐U) is associated with greater durability.
The COVID-19 pandemic and sleep medicine: a look back and a look ahead
Khosla, Seema, Berneking, Michael , Cheung, Joseph , Epstein, Lawrence J., Meyer, Brittany, Ramar, Kannan , So, Jennifer Y. , Sullivan, Shannon, Wolfe, Lisa F. , Gurubhagavatula, Indira , Cheung, Joseph , Beam, Elena

Mayo Clinic

Journal of Clinical Sleep Medicine | May 27, 2022 | Volume: 18 | Issue: 8 | Pages: 2045-2050

10.5664/jcsm.10102 | PMID 35621129 Get It

Embracing a curiosity‐driven approach in the microneurographic exploration of the human vagus nerves
Joyner, Michael J. , Klassen, Stephen A. , Joyner, Michael J , Klassen, Stephen A

Mayo Clinic

The Journal of Physiology | May 27, 2022 | Volume: 600 | Issue: 13 | Pages: 3009-3010

10.1113/jp283281 | PMID 35621702 Get It

Pulsatile Inferior Vena Cava Contrast Material Reflux in Carcinoid Heart Disease
Jang, Samuel , Ferrero, Andrea , Foley, Thomas A. , Atwell, Thomas D.

Mayo Clinic

Radiology: Imaging Cancer | May 27, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1148/rycan.220038 | PMID 35621525 Get It